The 2021 ESGO guidelines recommend that molecular classification should be encouraged in all endometrial carcinomas, including three immunohistochemical markers (p53, MSH6, and PMS2) and one molecular test (mutation analysis of the exonuclease domain of POLE) [4]. Here, TP53 is linked to endometrial carcinoma.